MAGEC2 (EP405) Rabbit Monoclonal Primary Antibody
Specialties: Genitourinary (GU) Pathology
Melanoma-associated antigen C2 (MAGEC2), encoded by the testis cancer gene CT10, belongs to a family of proteins that bind E3 RING ubiquitin ligases via a common MAGE homology domain.1-3 The MAGE-RING complexes that are formed enhance the activity of the ubiquitin ligase binding partners. In vitro studies suggest that MAGEC2, which binds to TRIM28, is involved in tumorigenesis through the increased degradation of p53.4 In germ cell tumors, aberrant expression of MAGEC2 is exhibited in seminomas, but is absent in yolk sac tumor and embryonal carcinoma.5-7
- Gure AO, et al. CT10: a new cancer-testis (CT) antigen homologous to CT7 and the MAGE family, identified by representational-difference analysis. Int J Cancer. 2000;85(5):726-32
- Lee AK, et al. A comprehensive guide to the MAGE family of Ubiquitin Ligases. J Mol Bio. 2017;429(8):1114-1142
- Doyle JM, et al. MAGE-RING Protein Complexes Comprise a Family of E3 Ubiquitin Ligases. Mol Cell. 2010;39(6):963-974
- Zhuang R, et al. Generation of monoclonal antibodies to cancer/testis (CT) antigen CT10/MAGE-C2. Cancer Immun. 2006;6:7
- Bode PK, et al. MAGEC2 is a sensitive and novel marker for seminoma: a tissue microarray analysis of 325 testicular germ cell tumors. Mod Path. 2011;24:829-835
- Chen YT, et al. Chromosome X-encoded cancer/testis antigens show distinctive expression patterns in developing gonads and in testicular seminoma. Hum Reprod. 2011;26(12):3232-43
- Weissferdt A, et al. Primary mediastinal seminomas: a comprehensive immunohistochemical study with a focus on novel markers. Hum Pathol. 2015;46(3):376-83
Specifications
- Reactivity: paraffin
- Control: Seminoma (Nuclear)
- Dilution Range: 1:25-1:50 *
Package Inserts
IFU
- IVD Rev. 0.0 (CMC47731000)
Have a different keycode?
Click Here
Learn how to obtain your SDS
Ordering Information
For in vitro diagnostic (IVD) use in USA
| 0.1 mL concentrate | 477R-14 |
| 0.5 mL concentrate | 477R-15 |
| 1.0 mL concentrate | 477R-16 |
| 1.0 mL predilute ready-to-use | 477R-17 |
| 7.0 mL predilute ready-to-use | 477R-18 |
For research use only (RUO) in Canada
| 0.1 mL concentrate (RUO) | 477R-14-RUO |
| 1.0 mL concentrate (RUO) | 477R-16-RUO |
| 1.0 mL predilute ready-to-use (RUO) | 477R-17-RUO |
| 7.0 mL predilute ready-to-use (RUO) | 477R-18-RUO |
For in vitro diagnostic (IVD) use in Europe
| 0.1 mL concentrate | 477R-14 |
| 0.5 mL concentrate | 477R-15 |
| 1.0 mL concentrate | 477R-16 |
| 1.0 mL predilute ready-to-use | 477R-17 |
| 7.0 mL predilute ready-to-use | 477R-18 |
For research use only (RUO) in Japan
| 0.1 mL concentrate (RUO) | 477R-14-RUO |
| 1.0 mL concentrate (RUO) | 477R-16-RUO |
| 1.0 mL predilute ready-to-use (RUO) | 477R-17-RUO |
| 7.0 mL predilute ready-to-use (RUO) | 477R-18-RUO |
To request information on this product in additional countries, please click the button below.
